Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
No lost causes at Xilio and Lyell
The companies press on with vilastobart and IMPT-314... up to a point.
Investors don't buy Lyell's solid tumour Car-T success
The ROR1 data are sketchy, and lung toxicity clouds prospects.
